Palbociclib: tested on its own
42 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Not applicableReport a problem
- Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.RecruitingNCT03242382Phase 2Report a problem
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)Active, not recruitingNCT06390839Phase 2Results postedReport a problem
- Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Active, not recruitingNCT04439201Phase 2Results postedReport a problem
- Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryTerminatedNCT03535506Phase 2Results postedReport a problem
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results postedReport a problem
- Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerCompletedNCT02692755Phase 2/3Results postedReport a problem
- Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedCompletedNCT02530320Phase 2Results postedReport a problem
- A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of PalbociclibCompletedNCT02334800Phase 1Results postedReport a problem
- Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyTerminatedNCT02334527Phase 2Results postedReport a problem
- Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01907607Phase 2Results postedReport a problem
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryCompletedNCT01864746Phase 3Results postedReport a problem
- A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk MyelodysplasiaTerminatedNCT01701375Phase 1Results postedReport a problem
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver CancerCompletedNCT01356628Phase 2Results postedReport a problem
- Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.CompletedNCT01291017Phase 2Results postedReport a problem
- A Study of PD 0332991 in Patients With Recurrent Rb Positive GlioblastomaTerminatedNCT01227434Phase 2Results postedReport a problem
- PD0332991 (Palbociclib) in Patients With Advanced or Metastatic LiposarcomaCompletedNCT01209598Phase 2Results postedReport a problem
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedNCT01037790Phase 2Results postedReport a problem
- An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.CompletedNCT00420056Phase 1Results postedReport a problem
- A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced CancerCompletedNCT00141297Phase 1Results postedReport a problem
- Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mgCompletedNCT06331715Phase 4Report a problem
- Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationWithdrawnNCT05371275Phase 2Report a problem
- Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyActive, not recruitingNCT05069038Phase 2Report a problem
- Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyStatus unknownNCT04318223Phase 2Report a problem
- High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)Status unknownNCT04247633Phase 2Report a problem
- Adjuvant Palbociclib in Elderly Patients With Breast CancerActive, not recruitingNCT03609047Phase 2Report a problem
- Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene AberrationsStatus unknownNCT03454919Phase 2Report a problem
- A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial TumorStatus unknownNCT03219554Phase 2Report a problem
- Histology-Independent Study of Palbociclib in Patients With Advanced CancerWithdrawnNCT03123744Phase 2Report a problem
- CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaCompletedNCT03110744Phase 2Report a problem
- Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)CompletedNCT03065621Phase 2Report a problem
- Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02905318Phase 2Report a problem
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2Report a problem
- Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2Report a problem
- Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaStatus unknownNCT02202200Phase 1/2Report a problem
- Study Of Palbociclib (PD-0332991) In Renal ImpairmentCompletedNCT02085538Phase 1Report a problem
- A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese SubjectsCompletedNCT02059330Phase 1Report a problem
- Randomized Phase II Study to Assess PD 0332991 in Breast CancerCompletedNCT02008734Phase 2Report a problem
- A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal TractCompletedNCT01844323Phase 1Report a problem
- A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male VolunteersCompletedNCT01756768Phase 1Report a problem
- Relative Bioavailability StudyCompletedNCT01602887Phase 1Report a problem
- A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionCompletedNCT01536743Phase 2Report a problem